GT Biopharma Stock Forecast

GTBP's stock price has decreased by -78.29% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 1 analyst with a 12-month price forecast for GT Biopharma stock has a target of 11, which predicts an increase of 530.37% from the current stock price of 1.75.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$11	$11	$11	$11
Change	+530.37%	+530.37%	+530.37%	+530.37%

Analyst Ratings

According to 1 stock analyst, the rating for GT Biopharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jul '24	Aug '24	Sep '24	Oct '24	Nov '24	Dec '24
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	1	1	1	1	1	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jonathan Aschoff Roth MKM	Roth MKM	Strong Buy Initiates $11	Strong Buy	Initiates	$11	+530.37%	Dec 2, 2024
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $150	Strong Buy	Reiterates	$150	+8,495.99%	Aug 8, 2023
Tony Butler EF Hutton	EF Hutton	Hold Reiterates $60	Hold	Reiterates	$60	+3,338.40%	Aug 7, 2023
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $150	Strong Buy	Reiterates	$150	+8,495.99%	Jun 5, 2023
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $150	Strong Buy	Reiterates	$150	+8,495.99%	May 17, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-11.02

from -5.64

EPS Next Year

-0.72

from -11.02

Fiscal Year	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2027
Period Ending	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2027
Revenue	-	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-	-
EPS	-342.62	-193.58	-61.81	-19.66	-5.64	-11.02	-0.72	-
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2024	2025	2027
High	n/a	n/a	n/a
Avg	n/a	n/a	n/a
Low	n/a	n/a	n/a

Revenue Growth

Revenue Growth	2024	2025	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

EPS Forecast

EPS	2024	2025
High	-11.34	-0.75
Avg	-11.02	-0.72
Low	-10.58	-0.70

EPS Growth

EPS Growth	2024	2025
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.